Table 4.
Treatment-related adverse events
| Adverse events | All grades | Grade ≥ 3 | ||||
|---|---|---|---|---|---|---|
| Group | P value | Group | P value | |||
| SBRT + LEN (n = 37) | LEN (n = 77) | SBRT + LEN (n = 37) | LEN (n = 77) | |||
| Any adverse event, n (%) | 34 (91.9%) | 69 (89.6%) | 0.962 | 7 (18.9%) | 12 (15.6%) | 0.655 |
| Hypertension, n (%) | 10 (27.0%) | 24 (31.2%) | 0.651 | 2 (5.4%) | 6 (7.8%) | 0.940 |
| Nausea/vomiting, n (%) | 8 (21.6%) | 21 (27.3%) | 0.517 | 1 (2.7%) | 3 (3.9%) | 1.000 |
| Proteinuria, n (%) | 6 (16.2%) | 16 (20.8%) | 0.563 | 0 (0%) | 0 (0%) | – |
| Peripheral edema, n (%) | 1 (2.7%) | 3 (3.9%) | 1.000 | 0 (0%) | 0 (0%) | – |
| Fatigue, n (%) | 9 (24.3%) | 23 (29.9%) | 0.537 | 0 (0%) | 0 (0%) | – |
| Anorexia, n (%) | 9 (24.3%) | 16 (20.8%) | 0.668 | 1 (2.7%) | 0 (0%) | 0.330 |
| Abdominal pain, n (%) | 8 (21.6%) | 15 (19.5%) | 0.928 | 1 (2.7%) | 1 (1.3%) | 0.546 |
| Constipation, n (%) | 3 (8.1%) | 8 (10.4%) | 0.962 | 0 (0%) | 0 (0%) | 1.000 |
| Diarrhea, n (%) | 10 (27.0%) | 18 (23.4%) | 0.672 | 1 (2.7%) | 1 (1.3%) | 0.546 |
| Rash, n (%) | 1 (2.7%) | 6 (7.8%) | 0.520 | 0 (0%) | 0 (0%) | – |
| Hand-foot syndrome, n (%) | 1 (2.7%) | 8 (10.4%) | 0.292 | 0 (0%) | 1 (1.3%) | 1.000 |
| AST/ALT elevation, n (%) | 8 (21.6%) | 13 (16.9%) | 0.787 | 1 (2.7%) | 0 (0%) | 0.330 |
| Thrombocytopenia, n (%) | 6 (16.2%) | 6 (7.8%) | 0.170 | 0 (0%) | 0 (0%) | – |
| Leukopenia, n (%) | 5 (13.5%) | 5 (6.5%) | 0.290 | 0 (0%) | 0 (0%) | – |
| Fever, n (%) | 1 (2.7%) | 4 (5.2%) | 0.543 | 0 (0%) | 0 (0%) | – |
| Joint pain, n (%) | 0 (0%) | 4 (5.2%) | 0.302 | 0 (0%) | 0 (0%) | – |
AST aspartate aminotransferase, ALT alanine aminotransferase, SBRT stereotactic body radiotherapy, LEN lenvatinib